Ocular Therapeutix Inc (OCUL) Darts Higher on Drug Data

Upbeat trial data on eye drug Dextenza has Ocular Therapeutix Inc (NASDAQ:OCUL) catching fire

Nov 14, 2016 at 10:29 AM
facebook X logo linkedin


Ocular Therapeutix Inc (NASDAQ:OCUL) is exploding this morning, after the drugmaker announced encouraging topline results for its experimental eye drug Dextenza. At last check, the biotech stock is 11.8% higher at $7.68, and once again testing resistance at its 200-day moving average, while its options are flying off the shelves.

At last check, intraday options volume for OCUL ranks in the 100th percentile of its annual range. Not to mention, the contracts are running at 13 times the expected intrday rate. That said, the stock's average daily options volume is low on an absolute basis, at a mere 331 contracts.

Short-term speculators could be uncomfortable with this morning's move higher. OCUL sports a Schaeffer's put/call open interest ratio (SOIR) of 0.84, which ranks in the put-skewed 80th percentile of its annual range. Meanwhile, for those looking to place near-term bets on the biotech stock, now is a good time. OCUL's Schaeffer's Volatility Index (SVI) of 99% sits in the low 7th annual percentile, suggesting modest volatility expectations are being priced in at the moment.

Elsewhere, short interest is high on the shares. Over 24% of OCUL's float is dedicated to these bearish bets. At the stock's average trading volume, it would take more than eight sessions for short sellers to cover -- which could be fueling today's rally, as these traders may be attempting to limit their losses.

Over the long term, though, bears have had the upper hand when it comes to Ocular Therapeutix Inc (NASDAQ:OCUL). Year-to-date, the stock has shed nearly 19% of its value, and is still a long way from filling its early June bear gap.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI